Next Challenge for AI in Pharma: Connecting Data, Systems and Workflows

AI in pharma is expanding across drug discovery, clinical development, real-world evidence, pharmacovigilance, commercial operations, and digital healthcare. But as pharmaceutical companies adopt more specialized AI technologies, another challenge is becoming harder to ignore: connecting those technologies with the data, systems, and workflows already running the business.

A pharmaceutical organization may use one platform for molecular research, another for clinical trials, another for real-world evidence, and different systems for regulatory, commercial, and patient-facing operations. Each platform may solve a specific problem well. The difficulty starts when the information generated by one system needs to become useful somewhere else.

That is where the next phase of pharmaceutical AI becomes interesting. The competitive advantage may not come from simply having more AI tools. It may come from how effectively those tools work together.

AI in Pharma Is Becoming an Ecosystem

The pharmaceutical industry has moved well beyond the early stage of asking whether AI role in drug development. AI is now being explored across the lifecycle, from identifying potential therapeutic targets and designing molecules to supporting clinical trials, analyzing real-world data, monitoring safety, and improving commercial decision-making. The FDA has reported a significant increase in drug-development submissions containing AI components across nonclinical, clinical, postmarketing, and manufacturing activities.

This growth is creating a more specialized technology environment. A company may not need one system that does everything. Instead, it may need several systems that perform specific tasks and communicate with each other.

That changes the technology question. Instead of asking only, “Which AI platform should we buy?”, pharmaceutical leaders increasingly need to ask, “How will this technology connect to our existing data, applications, teams, and workflows?”

From AI Models to Connected Workflows

An AI model can generate a prediction, classification, recommendation, or summary. But that output has limited value if it remains isolated from the process where someone needs to use it.

Consider clinical trial recruitment. An AI system could analyze available patient information and identify people who may meet certain trial criteria. That is useful, but it is only the beginning. The result may need to reach a clinical research team, connect with the relevant trial system, undergo professional review, and then become part of the enrollment process.

The complete workflow might involve patient data, AI analysis, researcher review, trial-management software, and follow-up actions. The model is important, but the connection between the model and the workflow is what makes the capability operational.

This principle applies across pharma. AI can generate an insight, but integration determines whether that insight becomes part of a real process.

Where Pharma Predictive Analytics Fits

Pharma predictive analytics is another example of why integration matters. Predictive models can analyze historical and current information to identify patterns associated with demand, patient populations, clinical trial enrollment, site performance, safety signals, or commercial activity.

But a prediction sitting inside an analytics dashboard does not automatically create value. The relevant team needs to receive the information, understand what it means, and have a defined process for responding to it.

A stronger architecture connects the data source to the predictive model and then connects the output to the appropriate workflow. This can turn predictive analytics from a reporting capability into a decision-support mechanism that fits into everyday operations.

The Integration Problem Across Drug Development

Drug discovery provides another clear example. AI can help researchers explore biological data, identify potential targets, screen compounds, predict molecular properties, and prioritize candidates for further investigation. Recent research has demonstrated the growing movement of AI from computational drug discovery toward clinical development.

However, drug development does not happen inside one application. Research data can move through laboratory systems, scientific databases, analytics platforms, research applications, and development processes. If those environments remain disconnected, teams may spend significant effort moving, validating, and interpreting information manually.

The challenge therefore becomes broader than model development. Pharmaceutical organizations need data pipelines, APIs, application integration, workflow automation, governance, and appropriate human review around the AI capability.

Real-World Evidence Adds Another Layer

Real-world data introduces a similar challenge. Pharmaceutical companies can work with information from EHRs, claims, registries, laboratory systems, pharmacy records, and other healthcare sources to understand treatment patterns and patient populations.

AI can help analyze these datasets, but real-world information can be fragmented and heterogeneous. Without appropriate data integration and governance, even a sophisticated model may struggle to produce reliable and useful results.

The value therefore comes from combining data infrastructure, analytics, AI, and domain expertise. The model is part of the architecture rather than the entire architecture.

Digital Pharmacy Extends the Opportunity

The AI opportunity also extends beyond research and development. Digital pharmacy is creating another environment where AI, software, healthcare data, automation, and patient experience intersect.

For example, an on-demand pharmacy delivery app may need to manage medicine discovery, prescriptions, inventory, payments, fulfillment, delivery tracking, and customer communication. AI can potentially support demand forecasting, inventory planning, customer-service automation, order prioritization, and operational analytics.

But those capabilities need to work within the pharmacy platform. An AI model that forecasts demand but cannot communicate with inventory systems is not solving the complete operational problem. The technology has to connect with the systems responsible for taking action.

Digital Pharmacy Is Also Becoming More Patient-Centric

Patient-facing pharmacy technology creates another opportunity for AI-enabled workflows. A digital pharmacy app consultation can connect patients with pharmacists or other qualified healthcare professionals through supported digital channels, depending on the service model and applicable requirements.

The surrounding platform may need appointment scheduling, secure communication, prescription information, patient support, order management, and follow-up capabilities. AI can assist with administrative and information-processing tasks, but professional judgment remains important where healthcare decisions are involved.

This is a broader lesson for healthcare technology: automation should reduce unnecessary work without removing the human involvement that a particular process requires.

What Happens When Identity Becomes Part of the Workflow?

Another example is facial recognition software. In appropriate healthcare environments, facial recognition can support identity verification, authentication, access control, or other identity-related processes.

However, deploying such technology requires more than integrating a computer-vision model. Organizations need to consider consent, privacy, security, accuracy, data retention, access controls, and applicable regulations. They also need to define what happens when the system cannot confidently verify an individual.

This illustrates the same principle seen throughout pharma AI: technology needs to be designed around the complete workflow, including exceptions and human intervention.

Why Pharma AI Needs an Integration Layer

As pharmaceutical organizations adopt more specialized AI systems, an integration layer becomes increasingly important. That layer can connect data sources, APIs, AI models, enterprise applications, analytics platforms, and workflow automation.

A simplified architecture could look like:

Data → Integration → AI → Predictive Analytics → Application → Workflow → Human Decision

The architecture will vary by use case, but the principle remains consistent. AI should not operate as an isolated component when the value of its output depends on other systems and people.

This is particularly relevant in regulated environments where traceability, validation, security, governance, and accountability need to be considered throughout the implementation.

What Does It Take to Build an AI-Enabled Pharma Workflow?

A successful implementation usually starts with the problem rather than the technology. Pharmaceutical leaders need to understand where the current process creates delays, manual effort, inconsistent decisions, or limited visibility.

The next step is identifying the data required and determining where that information currently exists. From there, teams can assess the appropriate AI capability, integration requirements, workflow changes, security controls, and human review points.

This approach can prevent a common problem: building an impressive AI demonstration that cannot be integrated into the environment where employees actually work.

The Future of AI in Pharma Will Be More Connected

The future of AI in pharma is unlikely to be defined by one technology or one platform. It will involve a network of specialized capabilities connected through data, APIs, applications, automation, and human expertise.

Drug discovery AI may connect with scientific research environments. Predictive analytics may feed clinical or commercial workflows. Real-world evidence platforms may connect multiple healthcare datasets. Digital pharmacy applications may combine AI with patient-facing services and pharmacy operations.

The organizations that can connect these capabilities effectively may be better positioned to turn individual AI experiments into repeatable operational systems.

The next question for pharma leaders may therefore be less about how much AI they have and more about how well their AI works with everything else.

Where Hyena.ai Fits

This is where Hyena.ai can position itself beyond the crowded market of standalone AI tools.

Pharmaceutical and healthcare organizations may already have specialized platforms. What they may need next is the ability to connect those technologies with their own applications, data, APIs, and operational workflows.

Hyena.ai can support this broader implementation layer through AI application development, predictive analytics, healthcare and pharmaceutical software, system integration, workflow automation, digital pharmacy solutions, computer vision, and other AI-enabled applications.

The objective is not simply to introduce another AI capability. It is to build technology that fits the organization's existing environment and turns AI outputs into usable workflows.

The Real Opportunity

The pharmaceutical AI ecosystem will continue to grow. More specialized platforms will emerge, more datasets will become available, and more processes will become candidates for AI.

That is a positive development, but it also creates complexity.

Every new AI capability introduces another question about data, integration, security, workflow, ownership, and human oversight.

The companies that solve those connections effectively can help turn a collection of AI capabilities into a functioning technology ecosystem.

AI can generate the insight. Integration can move the insight. Workflow can turn it into action.

That is where the next phase of AI in pharma is likely to create value.

Hyena.ai helps organizations build and integrate AI-powered applications around real-world pharmaceutical, healthcare, and business workflows.

Planning a pharma AI, predictive analytics, digital pharmacy, or healthcare technology project? DM Hyena.ai to discuss your use case.